The Most Nutritious Foods for Brain Health
A practical breakfast, lunch, and dinner guide using nutrient-dense proteins, healthy fats, and high-fiber carbohydrates.
-
-
A Daily Guide to Better Brain Health for MCI and Early Dementia
A clear, step-by-step daily plan to support brain health and make life easier for people with mild cognitive impairment or early dementia.
-
Farmed Fish and Shrimp: The Public Health Trade-Offs of Modern Aquaculture
Aquaculture carries the highest antimicrobial use intensity of any food-animal sector (164.8 mg/kg). What the evidence shows about resistance, residues, and pathogens in farmed fish and shrimp, and why the answer is choosing seafood carefully, not avoiding it.
-
Do Leqembi and Kisunla Meaningfully Help?
Lecanemab slowed decline by 0.45 CDR-SB points (27%) in CLARITY AD; donanemab by 22–36% in TRAILBLAZER-ALZ 2. Does the small class-wide effect in Cochrane CD016297 cancel those results — and what do two widely shared podcast claims about harm and reversal get wrong?
-
Creatine and Cognition in APOE ε4 Carriers: What the Evidence Actually Shows
No randomized trial has tested creatine in mild cognitive impairment, and the only Alzheimer study is a 20-person uncontrolled pilot using 20 g/day. What that means for APOE ε4 carriers — and where the small memory signal in healthy older adults really stands.
-
Lecanemab vs Donanemab: Why the Amyloid Target Matters
Lecanemab binds soluble protofibrils and is dosed continuously; donanemab binds pyroglutamate plaque amyloid and can be stopped after clearance. How that difference shapes dosing, MRI schedules, and ARIA counseling for APOE ε4 carriers.
-
Why Do Some APOE4 Carriers Never Develop Dementia?
Some APOE ε4 carriers reach old age with Alzheimer’s pathology in the brain and their thinking intact. What separates them is partly genetic, partly the absence of other brain diseases, and partly not what you have been told.
-
I Have Two Copies of APOE4. Am I Going to Get Alzheimer’s?
Two copies of APOE ε4 makes Alzheimer’s biology in the brain close to universal with age. It does not make dementia universal. What the population data actually show about whether, and when.
-
Clinical Trial Evaluation Guide: Assessing Candidacy and Risk as an APOE ε4 Carrier
In CLARITY AD, lecanemab slowed decline on CDR-Sum of Boxes by 0.45 points over 18 months (95% CI −0.67 to −0.23; P<0.001), with amyloid-related imaging abnormalities involving edema or effusion in 12.6% of 1,795 participants. Those events are not evenly distributed across genotypes, and ε4 homozygotes carry the highest risk — which is why APOE genotyping now forms part of pre-treatment risk assessment. This guide covers registry search, the four criteria that disqualify most applicants, and what to ask a coordinator before consenting.
-
Physician Conversation Guides: Four Frameworks for APOE ε4 Carriers
A typical primary care visit runs fifteen minutes, and most clinicians encounter APOE results rarely and without clinical context. The two predictable failure modes are brisk reassurance that changes nothing, or an unplanned testing cascade. These four frameworks — consumer genetic result, biomarker request, cardiometabolic management, and referral for a symptomatic relative — are built on one principle: replace an unanswerable question with a specific one your physician can act on.